In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, highlights the need for moving CAR T-cell therapy into earlier lines of treatment in patients with multiple myeloma (MM). Earlier in the disease course, fewer mutations are present, and T-cells have been found to exhibit greater fitness, which is associated with improved outcomes following CAR-T. Due to the attrition rate seen in myeloma treatment, only 15% of patients make it to fourth-line therapy where CAR-T is available to them, despite trials such as CARTITUDE-4 (NCT04181827) indicating encouraging safety and efficacy of CAR-T in earlier lines. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
